BOD (psychedelic)

BOD, also known as 4-methyl-2,5,β-trimethoxyphenethylamine or as β-methoxy-2C-D, is a psychedelic drug of the phenethylamine, 2C, and BOx families. It is the β-methoxy derivative of 2C-D. The drug is taken orally. BOD has been encountered as a novel designer drug.

Use and effects

In his book PiHKAL, Alexander Shulgin lists BOD's dose range as 15 to 25mg orally and its duration as 8 to 16hours. Its reported effects include mild open-eye and moderate closed-eye visual changes, enhancement of conversation and sense of humor, and unpleasant physical effects such as nausea and lethargy.

BOD shows high affinity for the serotonin 5-HT_2A and 5-HT_2C receptors. It produces the head-twitch response, a behavioral proxy of psychedelic effects, in rodents. The head-twitch response induced by BOD can be blocked by both the serotonin 5-HT_2A receptor antagonist ketanserin and by the selective serotonin 5-HT_2C receptor antagonist SB-242084, suggesting involvement of both the serotonin 5-HT_2A and 5-HT_2C receptors in BOD's psychedelic-like effects. In addition to its psychedelic-like effects, BOD produces hypolocomotion and conditioned place preference in rodents. Conversely, it does not produce self-administration. Similarly to other serotonergic psychedelics, BOD has been found to produce neurotoxicity in rodents.

The chemical synthesis of BOD has been described.

Analogues of BOD include BOHD and BOB, among others.

BOB was first described in the scientific literature by Alexander Shulgin, Peyton Jacob III, and Darrell Lemaire in 1985. Subsequently, it was described in greater detail by Shulgin in his 1991 book PiHKAL. It emerged as a novel designer drug by the 2010s.

BOD is a controlled substance in Canada under phenethylamine blanket-ban language.

BOD is unscheduled in the United States, but purchase, sale, or possession for human consumption could be prosecuted under the Federal Analogue Act.